Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

January 1, 2022
J Immunother Cancer
https://pubmed.ncbi.nlm.nih.gov/35863821

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/35863821

Research summary

This study identifies and characterizes novel small-molecule inhibitors that disrupt the PD-1/PD-L1 interaction, aiming to enhance antitumor immune responses. Utilizing in silico screening, in vitro assays, and in vivo models, the researchers demonstrated that these compounds promote T-cell activation and infiltration into tumors. Notably, compound 69 showed significant efficacy in restoring T-cell function and reducing tumor growth.

Key outcome of the study

The novel small-molecule inhibitors effectively block PD-1/PD-L1 interactions, leading to enhanced cytotoxic T-cell infiltration and antitumor activity in humanized mouse models, highlighting their potential as immunotherapeutic agents.

Mouse model

Humanized PD-1 Knockin mouse model developed by genOway, engineered to express the human extracellular domain of PD-1, enabling the evaluation of human-specific PD-1/PD-L1 interactions and therapeutics in vivo.

TARGET:
PDCD1
PD-1, CD279

Keywords

Cancer immunotherapy, PD-1/PD-L1 blockade, Small-molecule inhibitors, T-cell activation, Tumor microenvironment

Technical specifications

Humanized Knockin model, PD-1 extracellular domain replacement, Immune checkpoint modulation, In vivo efficacy studies

Related products

Catalogue product

genO‑hPD‑1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Customized product

No items found.